High-dose ziprasidone-induced acute dystonia.

Area of Science:

• Psychiatry
• Clinical Pharmacology

Background:

• Ziprasidone is an atypical antipsychotic used for treating schizophrenia and bipolar mania.
• Limited clinical data exist on extrapyramidal symptoms (EPS) risks at ziprasidone doses exceeding 160 mg/day.

Observation:

• A case study of a patient with schizophrenia is presented.
• The patient initially tolerated ziprasidone 160 mg/day without EPS for several months.
• Upon increasing the dose to 240 mg/day, the patient experienced acute dystonic reactions.

Findings:

• This case suggests that acute dystonia, a type of EPS, can emerge at higher ziprasidone doses (240 mg/day) even in patients who previously tolerated lower doses (160 mg/day).
• The findings highlight a potential dose-dependent relationship between ziprasidone and the risk of acute dystonic reactions.

Implications:

• Clinicians should be vigilant for EPS, particularly acute dystonia, when increasing ziprasidone dosage.
• This observation underscores the importance of careful dose titration and monitoring for adverse effects in patients treated with ziprasidone.
• Further research into dose-related EPS risks of ziprasidone is warranted.